Navigation Links
Bivona® Fome-Cuf® Wire Reinforced Endotracheal Tube Kits

ProductsBivona® Fome-Cuf® Wire Reinforced Endotracheal Tube Kits
Company Portex
Item Bivona® Fome-Cuf® Wire Reinforced Endotracheal Tube Kits
Features 
  • The Cuff Maintenance Device (CMD™), a 60 mL syringe with an attached 3-way stopcock, directly measures cuff volume and simplifies routine cuff maintenance
  • The hydrophobic nature of the silicone tube makes protein adhesion difficult, reducing bacterial growth on the tube
  • Fome-Cuf® material automatically adjusts to changes in the trachea and helps protect from aspiration
  • 10 units per case
    • Description Fome-Cuf® Oral/Nasal Wire Reinforced Endotracheal Tube Kits (silicone) Magill

    Each kit is packaged individually and includes a SidePort™ AutoControl™ airway connector, Cuff Maintenance Device (CMD™), and 15 mm ISO connector.

    The wire reinforcement provides maximum patient safety by helping to ensure an open airway.

    The integral stainless steel reinforcing wire provides a safe, kink resistant airway, regardless of head or neck position, or manipulation of the tube.
    Info Portex
    Customer Service: (603) 352-3812
    Web site: http://www.smiths-medical.com

    Related medicine products :

    1. Bivona® Intubation Stylet - Large
    2. Bivona® Intubation Stylet - Small
    3. Bivona® Fixed-Flange Hyperflex™ Extra Length Tracheostomy Tubes
    4. Bivona® Mid-Range Aire-Cuf® Adjustable Neck Flange Hyperflex™ Tracheostomy Tubes
    5. Bivona® TTS™ Adjustable Neck Flange Hyperflex™ Tracheostomy Tubes
    6. Bivona® Uncuffed Adult Tracheostomy Tubes
    7. Bivona® Mid-Range Aire-Cuf® Tracheostomy Tubes
    8. Bivona® TTS™ Tracheostomy Tubes
    9. Bivona® Laryngectomy Tubes
    10. Bivona® Mid-Range Aire-Cuf® and Fome-Cuf® Tracheostomy Tubes with Talk Attachment
    11. Bivona® Sleep Apnea Tracheostomy Tubes
    Surgiflex® WAVE XP™ Handpiece and Pump, without probe shaft
    Surgiflex® WAVE XP™ Handpiece and Pump
    SUCTION IRRIGATION: StrykeFlow PS
    SUCTION IRRIGATION: StrykeFlow 2
    Medicine Products:
    (Date:12/4/2009)...c. 4 While Congress deb...th care costs, Leapfrog,s purchaser members point ...ering the best quality care in the nation while at...our urban, eight children,s and three rural hospit...ased on results from The Leapfrog Hospital Survey....
    (Date:12/4/2009)...tists at Johns Hopkins publishing in the December ...e by a gene called "Twist" may be the proverbial r... that drive aggressive, metastatic breast cancer f...ent work suggesting that it is a relatively rare s... breast cancer, scientists have surmised that this...
    (Date:12/4/2009)...ntal tourism is a phenomenon that was started by p...high price of dental work in the US, Canada, and o...ental care, people have found that Mexican Dental ...tination. , (PRWEB) Decem...an 6 years, Mexican Dental Vacation is seeing thei...
    (Date:12/4/2009)...RNewswire/ -- Substantial progress has been made o...s ability to diagnose and treat epilepsy and its c...ement has not reached most of the 50 million peopl...hree million people in the United States who have ...er, M.D., president of the American Epilepsy Socie...
    (Date:12/4/2009)...ering drugs known as statins are among the most pr...researchers at Fred Hutchinson Cancer Research Cen...ransplant patients from one of the most serious co...ft-versus-host disease, or GVHD. The findings are ...l Blood . , In a retrospective study of 567 pati...
    Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2
    ...r osteoarthritis of the knee back to the future.Th...helps relieve pain and other symptoms better than ...ation of leeches to treat pain is an ancient medic...s, such as in treating postoperative complications...
    ...by viral cold are common in preschoolers. These at... frequency disappears by school age. //The current...eroids at the first sign of an attack. But whether...atory symptoms or the need for hospital admission....
    ...diagnosed with type 2 diabetes and now research sh...eater risk for a heart attack and stroke. //Specif...d with type 2 diabetes are 14-times more likely to...oing to get heart disease, heart attacks and strok...
    ...soon be fighting a losing battle. Scientists from ...uccessfully stopped the tuberculosis pathogen's ab...cally hides out in the immune system in a cell cal...s TB. Thus far, all of the research has been done ...
    ...on condition that can be fatal. It is defined as a...lly due to a blood clot, //which blocks a coronary...for a pulmonary embolism, a new study shows a new ...t 600,000 Americans develop a pulmonary embolism a...
    ...eir mouths. But as children get older, they become...y if they have not tried it before. Green veget... scientists say thousands of years ago toxins in p...ous of certain food types as youngsters. Resear...
    Other Medicine News:
    (Date:12/4/2009)...Neb., Dec. 4 Amber Pharmacy announ...creditation Commission for Health Care, Inc. (ACHC... years, Amber Pharmacy has provided comprehensive ...ique needs of specialized conditions. Amber Pharma...transplant programs. They work with over 170 trans...
    (Date:12/4/2009)...AKE CITY, Dec. 4 Dynatro... signed a sole-source vendor agreement to provide ...Physical Therapy with 65 clinics located in Tennes...d the sole-source supplier to Benchmark Physical T...esident of sales and marketing at Dynatronics. "Be...
    (Date:12/4/2009)..., WASHINGTON, Dec. 4 /PRNewswire-USNewswire/ ...eport published by the Pharmaceutical Research a...fies 97 new drugs and vaccines in development for ...ort found that the 97 products in development inc...e either in human clinical trials or awaiting appr...
    Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 1FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 3FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 4FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 5FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 6FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 7U S Census Bureau Daily Feature for July 21 52174 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 2UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 3UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 4